BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for Emerging E-Selectin Antagonists in the Management of AML

Release Date: June 30, 2023

Expiration Date: June 30, 2024

Activity Overview

This Burst Expert Illustrations and Commentaries^TM is a blend of modular education through a text-and-audio format, including a video animation, to provide an overview of current and emerging treatment strategies for patients with acute myeloid leukemia (AML). In this program, hear an expert faculty provide commentary on unmet needs in AML and review a novel therapeutic approach of E-selectin inhibition. The activity is enriched with the use of video animation to illustrate the mechanism of action of e-selection inhibition and its potential role in enhancing currently approved AML therapeutics. This unique format is designed to help clinicians delve into novel therapeutics in the management of AML and to ultimately improve outcomes for their patients with this disease.

Target Audience

This educational activity is directed toward hematologic and medical oncologists involved in the treatment of AML.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify unmet needs in AML and the mechanistic rationale underlying clinical trial evaluation of emerging therapies targeting E-selectin in AML
• Determine the implications of recent efficacy and safety evidence on E-selectin antagonists in context of evolving treatment paradigms in AML management
• Identify patients with AML who may benefit from clinical trial participation in studies evaluating emerging strategies in the field of AML care

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.